Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Delisting risk
confidence 92%
filed 2026-06-15
AIM ImmunoTech disclosed receipt of a letter from NYSE Regulation on June 12, 2026, confirming regained compliance with NYSE American continued listing standards. The filing explicitly references resolution of previously identified deficiencies under Section 1003(a)(i), (ii), and (iii) of the Company Guide and removal of the ".BC" (below compliance) indicator from the trading symbol. This is a material delisting-risk event because it documents the company's transition from noncompliance status back to compliance, directly addressing a prior listing threat.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-06-15
Item 7.01
The filing discloses resolution of a material delisting risk. Northann Corp. received a non-compliance notice from NYSE American on December 8, 2025 for failing to meet continued listing standards under Section 1003(a)(i) of the Company Guide. The company subsequently regained compliance on June 10, 2026, after demonstrating compliance for two consecutive quarters, resulting in removal from the noncompliant issuers list. This is a material event affecting the registrant's listing status and investor confidence.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-15
Item 3.01
ESS Tech received a written notice from NYSE on June 9, 2026, indicating failure to satisfy the continued listing standard under Section 802.01C due to average closing price below $1.00 per share. The company has a six-month cure period and may pursue remedies including a reverse stock split to regain compliance.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-12
Item 3.01
Soligenix received a written notice from Nasdaq on June 10, 2026, indicating noncompliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company has 180 calendar days (until December 7, 2026) to regain compliance, with explicit warning that failure to do so will result in delisting notification.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-12
Item 3.01
Adagio Medical received a notice from Nasdaq on June 12, 2026, that its common stock failed to comply with Nasdaq Listing Rule 5550(a)(2) due to a minimum bid price below $1.00 per share for 30 consecutive business days. The Company has 180 calendar days until December 9, 2026, to regain compliance, with a potential second 180-day period available if certain conditions are met. Failure to regain compliance will result in delisting notification. This is a material disclosure of delisting risk under Item 3.01.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-06-12
EX-99.1
XORTX announces a voluntary election to delist its common shares from the TSX Venture Exchange (TSXV), effective immediately upon Board approval. While this is a voluntary delisting (not a forced delisting due to non-compliance), it represents a material change in the registrant's listing status and trading accessibility for shareholders. The company will maintain its Nasdaq listing, but the removal of the TSXV dual listing affects the total mix of information available to investors regarding trading venues and regulatory obligations. This falls squarely within the delisting_risk taxonomy as a notice of delisting or transfer of listing (Item 3.01 equivalent).
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-12
Item 7.01
Flutter Entertainment disclosed its intention to delist ordinary shares from the London Stock Exchange via RNS announcement on June 12, 2026. This is a material event affecting the registrant's listing status and would significantly impact investors' ability to trade shares on the primary exchange. The disclosure of delisting intention directly triggers Item 3.01 classification (though filed under Item 7.01 as Regulation FD Disclosure).
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-06-12
EX-99.1
The press release discloses that Akanda received notice on May 20, 2026 of non-compliance with Nasdaq Listing Rule 5250(c)(1) due to failure to timely file its Form 20-F annual report, and subsequently regained compliance on June 10, 2026 after filing the Form 20-F on June 9, 2026. This is a delisting-risk event: the company faced a material threat to its continued listing status on Nasdaq, which would materially affect a reasonable investor's assessment of the registrant's trading status and market access.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-12
Item 3.01
BiomX received notice from NYSE Regulation on June 10, 2026 accepting the Company's compliance plan to regain compliance with continued listing standards after failing to maintain required stockholders' equity levels (stockholders' deficit of $1.3 million as of December 31, 2025). The Company has been granted a plan period through September 25, 2027, but faces potential delisting proceedings and a ".BC" indicator if it fails to regain compliance or make satisfactory progress.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-06-12
The 6-K discloses that Guardforce AI failed to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share by the June 10, 2026 deadline. Although Nasdaq granted an additional 180-day cure period until December 7, 2026, the filing explicitly states "In the event the Company does not regain compliance by December 7, 2026, the Company may face delisting." This is a material delisting risk disclosure under Item 3.01 equivalent.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 99%
filed 2026-06-12
Item 3.01
Cyabra received formal notice from Nasdaq on June 9, 2026, of non-compliance with two critical listing rules: the Market Value of Publicly Held Shares Rule (MVPHS) and the Minimum Bid Price Rule. The company has 180 days to regain compliance or face delisting, with the option to appeal or transfer to the Capital Market. This is a textbook delisting-risk disclosure under Item 3.01, materially affecting the company's continued public trading status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-12
La Rosa Holdings disclosed two material delisting risks under Item 3.01: (1) noncompliance with Nasdaq Listing Rule 5250(c)(1) due to delinquent Form 10-Q filing, with 180 days to regain compliance by October 12, 2026; and (2) noncompliance with Nasdaq Listing Rule 5550(b)(1) due to negative stockholders' equity of $(1,848,252) versus the $2,500,000 minimum requirement, with 45 days to submit a remediation plan and 180 days to evidence compliance by December 7, 2026. The filing explicitly states "There can be no assurance that the Company will be able to regain or maintain compliance with all applicable continued listing requirements," indicating material delisting risk.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-12
Item 3.01
BioCardia received a Nasdaq delisting notice on April 10, 2026 for failing to maintain the $2.5 million minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1). Although the company claims to have regained compliance through an ATM offering that raised $4.9 million in net proceeds, Nasdaq retains ongoing monitoring authority and explicitly warns that "if at the time of its next periodic report the Company does not evidence compliance, it may be subject to delisting." This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-12
Item 3.01
Genprex received a formal delisting notice from Nasdaq on June 10, 2026, for failure to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company is ineligible for a compliance period due to a reverse stock split effected on October 21, 2025, and must request a hearing before a Nasdaq Hearings Panel to avoid delisting.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-06-12
EX-99.1
The exhibit announces that Cuprina has regained compliance with Nasdaq's minimum bid price requirement after receiving a Staff Delisting Determinations Letter on May 29, 2026, indicating the company's stock had closed below $1.00 for 30 consecutive business days. Although the announcement is positive (regaining compliance), the core disclosure is the resolution of a delisting risk event — the company was previously non-compliant and faced a scheduled hearing before the Nasdaq Hearing Panel on July 7, 2026, which has now been cancelled due to restored compliance. This is a material event affecting the registrant's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-12
Item 3.01 discloses that OFA Group received notice from Nasdaq on June 9, 2026, that it has failed to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days. The company has been granted a second 180-day compliance period (until December 7, 2026) to regain compliance, with explicit warning that failure to do so will result in delisting notification and potential loss of Nasdaq listing. This is a material delisting risk event requiring disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-12
Item 3.01
The filing discloses a Nasdaq deficiency notice under Item 3.01 regarding failure to satisfy the stockholders' equity requirement (Nasdaq Listing Rule 5550(b)(1)). The Company reported negative stockholders' equity of $(12,447,801) as of December 31, 2025, well below the $2,500,000 minimum. While Nasdaq granted an extension through October 12, 2026, the Company faces delisting if it fails to evidence compliance by that deadline or upon filing its 2026 periodic report. This is a material delisting risk event.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-12
The filing discloses Item 3.01 regarding a Nasdaq compliance notice dated June 12, 2026. While the notice confirms the Company has now achieved compliance with Listing Rule 5250(c)(1) (periodic filing requirement) and closes a prior non-compliance matter from May 21, 2026, the disclosure itself documents a delisting risk event—the Company had previously failed to satisfy a continued listing standard and received a notice of non-compliance. The resolution of this matter is material to investors as it addresses a direct threat to the Company's continued listing on Nasdaq.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-06-12
The filing's primary disclosure is Item 3.01, which reports MicroVision's application to transfer listing from The Nasdaq Global Market to The Nasdaq Capital Market due to failure to maintain the $1.00 minimum bid price requirement. The company previously received a deficiency notice in January 2026 and now seeks a transfer to avoid delisting, with an additional 180-calendar-day grace period to regain compliance. This is a material delisting-risk event that would significantly affect investor assessment of the company's exchange status and trading continuity.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-12
Celularity received written notice from Nasdaq on June 9, 2026, that its Market Value of Listed Securities fell below the $35 million minimum required under Nasdaq Listing Rule 5550(b)(2). The company has been granted a 180-day compliance period (until December 7, 2026) to regain compliance, with explicit warning that failure to do so will result in delisting notification. This is a classic delisting risk disclosure under Item 3.01, material to any investor assessing the company's continued public market access.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-12
Item 3.01 discloses that NYSE American's Regulatory Staff determined Perfect Moment Ltd. failed to regain compliance with minimum stockholders' equity requirements by the end of the 18-month compliance period and is "no longer suitable for continued listing." The company's common stock will be suspended from NYSE American during the week of June 15, 2026, and transition to OTC Markets trading. This is a material delisting event that fundamentally affects the registrant's market access and liquidity.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-11
Item 3.01
Following completion of the merger, KalVista notified Nasdaq on June 10–11, 2026 of the consummation and requested delisting of its shares from The Nasdaq Global Market. Trading was halted effective June 10, 2026 and ceased on June 11, 2026, with the Company intending to file Form 25 and Form 15 to remove listing and terminate SEC registration.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-11
Item 3.01
GoHealth received a written notice from Nasdaq on June 9, 2026 determining to delist the Company's Class A common stock (GOCO) from Nasdaq, effective June 16, 2026. The delisting was based on the Chapter 11 bankruptcy filing, concerns about residual equity interests, and failure to maintain the $35 million minimum market value requirement under Nasdaq Listing Rule 5550(b)(2). This is a direct and material delisting event that removes the company's primary listing venue.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-11
Item 3.01
YHN Acquisition I Ltd received a Nasdaq deficiency notification on June 10, 2026, stating non-compliance with the minimum total holders requirement (400 holders) under Nasdaq Listing Rule 5450(a)(2). The company has 45 calendar days to submit a compliance plan and up to 180 days to evidence compliance, with the alternative of transferring to Nasdaq Capital Market. This is a classic delisting risk disclosure under Item 3.01, material to investors as it threatens the company's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-06-10
Item 8.01
InMed received a Nasdaq notice on March 27, 2026 that its closing bid price fell below the $1.00 minimum requirement under Nasdaq Listing Rule 5550(a)(2), creating delisting risk. Although the Company subsequently regained compliance by June 3, 2026, the disclosure centers on the failure to satisfy a continued listing rule and the remediation thereof—the core substance of delisting_risk. This is material to investors as it directly affects the registrant's exchange listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-06-10
Item 8.01
The filing discloses that Ribbon Acquisition Corp. regained compliance with Nasdaq Listing Rule 5250(f) following payment of a past due fee balance, resolving a non-compliance matter previously disclosed on June 5, 2026. While the company has now cured the violation, the disclosure of a listing rule breach and its resolution is material to investors assessing continued listing status and regulatory standing. The delisting_risk classification captures the materiality of listing compliance events, even when resolved.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-10
Item 3.01
BIO-key received formal notice from Nasdaq on June 5, 2026, that it failed to satisfy Nasdaq Listing Rule 5250(c)(1) by not filing its Form 10-Q for the period ended March 31, 2026. The notice explicitly states this serves as an additional basis for delisting and that a Nasdaq Hearing Panel will determine the Company's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-06-10
Item 8.01
The filing discloses a one-for-eight share consolidation explicitly intended "to assist the Company in maintaining compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market." This is a direct response to delisting risk — the Company is taking corrective action to avoid loss of listing status. While the consolidation itself is a routine corporate action, the material event is the underlying delisting compliance issue that triggered it.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-06-09
Item 8.01
The disclosure reports that CarParts.com has regained compliance with Nasdaq's minimum bid price requirement (Listing Rule 5450(a)(1)) after the closing bid price remained at $1.00 or greater for 10 consecutive business days. This is a delisting-risk event because it documents resolution of a prior non-compliance notice that threatened continued listing. The materiality is high because listing status directly affects investor access and trading liquidity.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-09
Item 3.01
Jasper Therapeutics received written notice from Nasdaq on June 3, 2026, that its voting common stock bid price closed below the $1.00 minimum requirement for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2). The company has been granted an initial 180-day compliance period (until November 30, 2026) to regain compliance, with potential for a second 180-day period if certain conditions are met. This is a classic delisting risk disclosure under Item 3.01, materially affecting investor assessment of the company's continued public trading status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-09
Item 3.01
The Company received notification from Nasdaq that it failed to meet the Minimum Public Holders Rule (Listing Rule 5550(a)(3)) and has been granted an extension through October 3, 2026 to regain compliance. This is a classic delisting risk disclosure under Item 3.01, indicating the Company is at risk of losing its Nasdaq listing if it cannot cure the deficiency within the extension period.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-09
Item 3.01
Professional Diversity Network received written notification from Nasdaq on June 5, 2026, that it failed to comply with Nasdaq Listing Rule 5550(a)(2) due to its closing bid price falling below $1.00 per share for 30 consecutive business days. The company has been granted a 180-calendar day compliance period until December 2, 2026, to regain compliance, with potential delisting if it fails to do so. This is a classic delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-06-09
Item 3.03
The Company effected a 1-for-20 reverse stock split solely to restore compliance with NASDAQ Capital Market's continued listing standards. This action addresses a material listing compliance failure and represents a significant delisting risk event.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-06-09
Item 8.01
The filing discloses that Flag Ship Acquisition Corp has regained compliance with Nasdaq Listing Rule 5250(c)(1) following prior non-compliance notices on April 17 and May 21, 2026 related to failure to timely file required periodic reports (Form 10-K and Form 10-Q). While the company has now cured the deficiency, the disclosure of delisting risk and its resolution is material to investors assessing the registrant's continued listing status and regulatory standing.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-09
Item 3.01
Following consummation of the business combination, Legato's listing transferred from NYSE American to Nasdaq, with Legato's units, ordinary shares, and warrants delisted from NYSE American and Einride's ADSs and warrants commencing trading on Nasdaq under ticker 'ENRD' on June 10, 2026.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-08
Item 3.01
aTyr Pharma received a deficiency notice on December 4, 2025, for failing to maintain a minimum closing bid price of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). Although the company was granted a second 180-day compliance period (until November 30, 2026) on June 3, 2026, the filing explicitly states that failure to regain compliance by that date will result in a delisting notice, with only the possibility of appeal. This is a material delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-06-08
Item 8.01
The filing discloses a delisting compliance matter under Nasdaq Listing Rule 5450(a)(1) regarding the Minimum Bid Price Requirement. Although the Company has now regained compliance as of June 5, 2026, the disclosure centers on the prior non-compliance notice (December 22, 2025) and the resolution of that delisting risk. This is a material event affecting the Company's listing status and investor confidence, even though the immediate threat has been resolved.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-06-08
The filing discloses a 1-for-40 reverse stock split effected on June 3, 2026, explicitly stated as being undertaken "solely to enable the Company to expeditiously restore compliance with the continued listing standards of the Nasdaq Stock Market...and Nasdaq's $1.00 minimum bid price requirements." This is a classic delisting-risk mitigation action—the company's stock price had fallen below Nasdaq's minimum bid price threshold, triggering the need for a reverse split to avoid delisting. The materiality is clear: failure to maintain listing compliance would be terminal to the company's public status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-08
Item 2.03
Vivos Therapeutics received a Nasdaq notice on June 5, 2026, that it failed to maintain the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2) from April 23 to June 4, 2026. The company has been granted a 180-day compliance period (until December 2, 2026) to regain compliance, with potential for a second 180-day period if certain conditions are met.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-08
Item 3.01
Nasdaq notified Inotiv on June 4, 2026 that its common shares will be delisted effective June 11, 2026, as a direct result of the company's Chapter 11 bankruptcy filing. The company does not intend to appeal the delisting determination.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-05
Item 8.01
Humacyte disclosed receipt of a Nasdaq deficiency notice on May 4, 2026, for failure to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1), followed by notification on June 5, 2026, that the company had regained compliance. This disclosure directly addresses delisting risk and continued listing status, which is material to investors assessing the registrant's ability to remain publicly traded.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-06-05
Item 8.01
The filing discloses that Standard BioTools has regained compliance with Nasdaq's minimum bid price requirement (Rule 5450(a)(1)) after previously falling below $1.00 per share for 30 consecutive business days on April 20, 2026. While the current disclosure is positive (resolution of the delisting risk), the underlying event—the prior non-compliance notice and threat of delisting—is material to investors and directly relates to the delisting_risk category. The company's ability to maintain listing is a fundamental concern for equity investors.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-05
Item 3.01
Nasdaq has issued a staff determination letter notifying Ribbon Acquisition Corp. of its decision to delist the Company's securities due to failure to pay $75,000 in required listing fees under Nasdaq Rule 5250(f). The Company intends to appeal but acknowledges "there can be no assurance that the Company will be successful in maintaining the listing of its securities on Nasdaq." This is a direct delisting notice triggering Item 3.01 disclosure.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-05
Arrive AI received a deficiency notice from Nasdaq on June 2, 2026, for failure to maintain the minimum bid price of $1.00 per share required under Nasdaq Listing Rule 5450(a)(1). The company has been given a 180-day compliance period until November 30, 2026, to regain compliance, with potential delisting if it fails to do so. This is a classic delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-05
Research Frontiers received two deficiency notification letters from Nasdaq on June 2, 2026, advising that the Company no longer satisfies the $1.00 minimum bid price requirement and the $35 million minimum Market Value of Listed Securities requirement for continued listing on The Nasdaq Capital Market. The Company has 180 calendar days until November 30, 2026, to regain compliance, with no assurance of success. This is a classic delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-05
Item 3.01
Driven Brands received a notice from Nasdaq on June 1, 2026 that it is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to delayed filing of its 1Q2026 10-Q. The company has 60 calendar days to submit a compliance plan and up to 180 days to regain compliance, with the risk of delisting if it fails to do so.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-04
The filing discloses Item 3.01 notification that Abpro Holdings' securities will be delisted from Nasdaq effective immediately due to failure to meet the minimum equity standard requirement under Nasdaq Listing Rule 5550(b)(1) by the February 16, 2026 deadline. The Nasdaq Listing and Hearing Review Council reaffirmed the delisting decision on May 28, 2026, and the company expects Nasdaq to file a Form 25 to deregister the securities. This is a terminal delisting event with material consequences for trading and liquidity.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-04
Item 3.01
The filing discloses that following the death of director Douglas Maine on June 1, 2026, the Company notified Nasdaq on June 2, 2026 that it is no longer in compliance with three critical Nasdaq Listing Rules: the majority independent director requirement (Rule 5605(b)(1)), the audit committee independence requirement (Rule 5605(c)(2)(A)), and the compensation committee independence requirement (Rule 5605(d)(2)(A)). Although Nasdaq has granted a cure period until the earlier of the next Annual Meeting or May 31, 2027, the filing explicitly states "there can be no assurance that Company will be able to regain compliance with the applicable Nasdaq Listing Rules" within the required timeframe, creating material delisting risk.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-04
The filing discloses that NYSE American accepted Volato's compliance plan on June 3, 2026, following a March 17, 2026 notice of non-compliance with continued listing standards (Sections 1003(a)(i) and 1003(a)(ii)). The company has until December 17, 2026 to regain compliance, with explicit warning that failure to do so or lack of progress "may initiate delisting proceedings." This is a material delisting risk event under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-04
Item 3.01
Smith-Midland received a notice from Nasdaq on May 29, 2026 stating non-compliance with Listing Rule 5250(c)(1) due to failure to timely file the Form 10-Q for the quarter ended March 31, 2026. While the notice has no immediate delisting effect, the company faces a July 28, 2026 deadline to file or submit a compliance plan, creating material delisting risk. This is a classic Item 3.01 disclosure of failure to satisfy a continued listing rule.
View raw filing on EDGAR →